Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ATOS
stocks logo

ATOS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.067
+33.34%
--
--
-0.070
+40%
--
--
-0.070
-0%
Estimates Revision
The market is revising No Change the revenue expectations for Atossa Therapeutics, Inc. (ATOS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -3.62%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-3.62%
In Past 3 Month
Wall Street analysts forecast ATOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATOS is 6.25 USD with a low forecast of 4.00 USD and a high forecast of 7.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ATOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATOS is 6.25 USD with a low forecast of 4.00 USD and a high forecast of 7.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.759
sliders
Low
4.00
Averages
6.25
High
7.75
Current: 0.759
sliders
Low
4.00
Averages
6.25
High
7.75
Craig-Hallum
NULL
to
Buy
initiated
$4
2025-06-05
Reason
Craig-Hallum
Price Target
$4
2025-06-05
initiated
NULL
to
Buy
Reason
Craig-Hallum initiated coverage of Atossa Therapeutics with a Buy rating and $4 price target.
Craig-Hallum
Craig-Hallum
Buy
initiated
$4
2025-06-05
Reason
Craig-Hallum
Craig-Hallum
Price Target
$4
2025-06-05
initiated
Buy
Reason
As previously reported, Craig-Hallum initiated coverage of Atossa Therapeutics with a Buy rating and $4 price target. The firm points out that Z-endoxifen is a novel and potent SERM that can treat all stages of breast cancer. As the primary therapeutic metabolite of tamoxifen, Z-endoxifen is de-risked and has demonstrated differentiated efficacy and an advantageous safety profile in multiple clinical studies, Craig-Hallum argues, adding that Z-endoxifen development is focused on metastatic breast cancer, which offers the fastest path to market and can strategically support future expansion to early disease settings. The most notable opportunity is prevention, where Z-endoxifen's ability to avoid menopausal-like side effects can support uptake in a large TAM of over 10M women at high-risk of developing breast cancer in the U.S. The firm believes Atossa is undervalued and sees opportunity for share appreciation as Z-endoxifen gains further validation with readouts from neoadjuvant studies expected next year and design details for a Phase III metastatic breast cancer study and initiation expected by year-end 2025.
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$7 → $7.25
2025-04-21
Reason
Ascendiant Capital
Edward Woo
Price Target
$7 → $7.25
2025-04-21
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$7
2025-03-26
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$7
2025-03-26
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$7
2025-03-12
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$7
2025-03-12
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$7
2025-01-30
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$7
2025-01-30
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Atossa Therapeutics Inc (ATOS.O) is -2.68, compared to its 5-year average forward P/E of -6.50. For a more detailed relative valuation and DCF analysis to assess Atossa Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.50
Current PE
-2.68
Overvalued PE
-0.15
Undervalued PE
-12.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ATOS News & Events

Events Timeline

(ET)
2025-12-04
08:10:00
Atossa Therapeutics Completes FDA Meeting to Advance (Z)-endoxifen
select
2025-12-02 (ET)
2025-12-02
08:20:00
Atossa and Insilico Publish Joint Study on (Z)-Endoxifen's Potential for Glioblastoma
select
2025-11-12 (ET)
2025-11-12
08:17:35
Atossa Therapeutics Announces Q3 Earnings Per Share of 7 Cents, Matching Expectations
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-04Newsfilter
Atossa Completes FDA Meeting to Accelerate (Z)-Endoxifen Development
  • FDA Meeting Outcome: Atossa completed a Type C meeting with the FDA on November 17, 2025, receiving feedback on expedited regulatory pathways for (Z)-endoxifen, which will help accelerate clinical development across multiple breast cancer indications.
  • Clinical Trial Progress: The company has completed multiple clinical trials involving nearly 800 participants and is preparing a dose-ranging study for metastatic breast cancer, which is expected to significantly shorten regulatory timelines and advance registrational development.
  • Innovative Drug Development: Atossa is developing a novel oral formulation of (Z)-endoxifen aimed at enhancing bioavailability, with clinical studies showing good tolerance at doses up to 360 mg/day, supporting further dose-range exploration.
  • Intellectual Property Support: The (Z)-endoxifen program is backed by a growing global intellectual property portfolio, including four recently issued U.S. patents, enhancing its market competitiveness and future growth potential.
[object Object]
Preview
9.0
11-17PRnewswire
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

  • Potential of (Z)-endoxifen in DMD: Atossa Therapeutics highlights the investigational therapy (Z)-endoxifen's multi-pathway efficacy in treating Duchenne Muscular Dystrophy (DMD) and associated pathologies, supported by a newly published hypothesis article and an upcoming scientific presentation.

  • Mechanisms of Action: The article details (Z)-endoxifen's pharmacological effects, including estrogen-receptor modulation and PKC inhibition, which may address key disease drivers like inflammation and mitochondrial dysfunction, potentially offering a more reliable therapeutic option compared to tamoxifen.

  • Focus on Female Carriers: Atossa's upcoming presentation will emphasize the significance of symptomatic female carriers of DMD, who may experience muscle-related symptoms and cardiomyopathy, underscoring the need for targeted therapies in this under-recognized population.

  • Strategic Development Plans: Atossa aims to leverage the findings to guide preclinical validation and clinical study designs, focusing on safety and efficacy assessments for (Z)-endoxifen, while exploring its potential as a complementary treatment alongside existing therapies for DMD.

[object Object]
Preview
9.0
11-06PRnewswire
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

  • Presentation of Research Findings: Atossa Therapeutics will present four abstracts on (Z)-endoxifen at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025, focusing on its role in breast cancer treatment and prevention.

  • Details of Poster Presentations: The presentations will cover various studies, including a multicenter trial on DCIS management, low-dose (Z)-endoxifen in the I-SPY2 trial, its function against ESR1 mutants, and a randomized trial comparing (Z)-endoxifen with exemestane for premenopausal women with ER+/HER2- breast cancer.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Atossa Therapeutics Inc (ATOS) stock price today?

The current price of ATOS is 0.7595 USD — it has increased 2.84 % in the last trading day.

arrow icon

What is Atossa Therapeutics Inc (ATOS)'s business?

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).

arrow icon

What is the price predicton of ATOS Stock?

Wall Street analysts forecast ATOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATOS is 6.25 USD with a low forecast of 4.00 USD and a high forecast of 7.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Atossa Therapeutics Inc (ATOS)'s revenue for the last quarter?

Atossa Therapeutics Inc revenue for the last quarter amounts to -9.25M USD, increased 44.89 % YoY.

arrow icon

What is Atossa Therapeutics Inc (ATOS)'s earnings per share (EPS) for the last quarter?

Atossa Therapeutics Inc. EPS for the last quarter amounts to -6012000.00 USD, increased 26.30 % YoY.

arrow icon

What changes have occurred in the market's expectations for Atossa Therapeutics Inc (ATOS)'s fundamentals?

The market is revising No Change the revenue expectations for Atossa Therapeutics, Inc. (ATOS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -3.62%.
arrow icon

How many employees does Atossa Therapeutics Inc (ATOS). have?

Atossa Therapeutics Inc (ATOS) has 13 emplpoyees as of December 05 2025.

arrow icon

What is Atossa Therapeutics Inc (ATOS) market cap?

Today ATOS has the market capitalization of 98.03M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free